
    
      The primary objective of this study is to investigate the durability of HBeAg seroconversion
      in patients with chronic hepatitis B virus infection (HBV) who have seroconverted while
      participating in a previous Gilead-sponsored study of adefovir dipivoxil.

      The secondary objective of this study is to investigate the durability of HBeAg loss in
      patients with chronic hepatitis B virus infection (HBV) who have experienced durable HBeAg
      loss while participating in a previous Gilead-sponsored study of adefovir dipivoxil.
    
  